(EMAILWIRE.COM, July 20, 2018 ) According to a new market research report "Patient Derived Xenograft/PDx Models Market by Type (Mouse & Rat), Tumor Type (Gastrointestinal, Gynecological, Respiratory), Application (Pre-Clinical Drug Development & Biomarker Analysis), End User (Pharma & Biotech, CRO) - Global Forecast to 2022", published by MarketsandMarkets™, the market is expected to reach USD 167.6 Million by 2022 from an estimated USD 77.4 Million in 2017, at a CAGR of 16.7%. The key factors driving the growth of this market include the growing demand for personalized medicine, continuous support for cancer research from the public as well as private sectors, and growth in the number of R&D activities in the pharmaceutical industry. The growing use of humanized PDX models is posing a lucrative opportunity in this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=121598251

The report analyzes the patient derived xenograft models market by type, tumor type, application, end user, and region. On the basis of type, the market is segmented into mice and rat models. The mice models segment is estimated to command the largest share of the global market in 2017. The rat models segment, on the other hand, is projected to register the highest CAGR from 2017 to 2022. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. The development of immunodeficient rats will drive the usage of rat models in PDX model generation. Based on tumor type, the PDX models market has been segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models such as head & neck tumors, sarcoma, and melanoma. In 2017, the gastrointestinal tumor models segment is expected to account for the largest share of the global market.

Based on application, the PDX models market has been broadly segmented into preclinical drug development & basic cancer research and biomarker analysis. In 2017, the preclinical drug development and basic cancer research segment is expected to account for the largest share of the global patient derived xenograft models market. Growth in this segment is mainly driven by the increasing number of research activities in the field of oncology drug research. On the basis of end user, the PDX models market has been segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the patient derived xenograft models market in 2017. The large share of this segment is due to the increasing expenditure on R&D by companies for drug development.

Get Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=121598251